AstraZeneca has announced that its HORIZON head-to-head study of Recentin (cediranib, AZD2171) versus Avastin (bevacizumab) in patients with first line metastatic colorectal cancer (CRC) is to go directly into phase III trials at 20mg.
But the company also revealed that the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) has told it that the BR24 phase II/III study of Recentin at 30mg in first line non-small cell lung cancer (NSCLC) will not continue into phase III.
AstraZeneca said some “clinical activity” was seen in the trials, but there appears to be an “imbalance in toxicity” and they will no longer progress.
John Patterson, AstraZeneca’s executive director for development, said: “Given there is such a high unmet patient need for more effective treatments in cancer, we are pleased that the HORIZON colorectal cancer programme has met its predefined criteria to continue recruitment into phase III.
“Due to the phase II/III trial design, HORIZON III is able to move directly into phase III utilising all the phase II data, and this saves valuable time in assessing the potential benefit of Recentin in the first line metastatic colorectal cancer setting.”
He added: “AstraZeneca supports the NCIC-CTG’s BR24 recommendation and is working with them to understand the data more fully in NSCLC.
“As evidence of clinical activity was seen in BR24, AstraZeneca remains committed to investigating the potential of Recentin in lung cancer and reducing the incidence of serious adverse events.”
Copyright Â© PA Business 2008